Treating patients with nonmetastatic clear-cell renal cell carcinoma with the tyrosine kinase inhibitor axitinib could not only prevent disease progression, but also shrink tumours before surgery, show the results of a phase II trial.
Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.
The P4 pain scale compares favorably with other commonly used measures for patients with severe knee osteoarthritis, a Canadian study has found.
The length of intravesical prostatic protrusion in men undergoing radical prostatectomy predicts the likelihood that they will develop incontinence following surgery, Korean researchers have shown.
Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research.
Nearly 1 in 10 cases of viral upper respiratory tract infections in infants and young children is complicated by acute bacterial sinusitis, often in conjunction with acute otitis media, a longitudinal cohort study has found.
Researchers have used a urine test to show that about a quarter of patients with supposedly treatment-resistant hypertension are actually failing to take their medications as prescribed.
DSM’s biomedical work brings new material innovation to market through the development of novel materials-based solutions that meet the present and future needs of the medical device and pharmaceutical industries.
Brain activity of babies in developing countries could be monitored from birth to reveal the first signs of cognitive dysfunction, using a new technique piloted by a London-based university collaboration.
STEM-Pharma is a management consulting firm specialized in healthcare and pharmaceutical market intelligence. The company delivers evidence-based recommendations on pharmaceutical growth opportunities in emerging markets.
OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.
The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.
Researchers at the University of Toronto say a sleep disorder that causes people to act out their dreams is the best current predictor of brain diseases like Parkinson's and Alzheimer's.
Interleukin Genetics, Inc. today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict™ Genetic Risk Test for periodontal disease.
Today's early morning highlights from the major news organizations, including marketplace news about the Novartis purchase of GlaxoSmithKline's oncology unit for $14.5 billion.
The effect of economic cuts on debt ravaged Greece included a dramatic rise in the number of men committing suicide, according to new research.
Plans to design a smart phone app that can detect leukaemia will be among the innovations presented by Northumbria University researchers at the Centre for Life this weekend.
GNYHA Services, Inc. and Essensa, Inc., leading group purchasing organizations serving acute care, alternate care, and non-healthcare markets, have added MedSnap ID to their portfolio of technology offerings.